更新于：2024-11-04
Pyrazinamide
吡嗪酰胺
更新于：2024-11-04
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1956-09-20), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (澳大利亚) |
登录后查看时间轴
结构
分子式C5H5N3O |
InChIKeyIPEHBUMCGVEMRF-UHFFFAOYSA-N |
CAS号98-96-4 |
关联
93
项与 吡嗪酰胺 相关的临床试验Shortened Regimen for Drug-susceptible TB in Children
Comparative Evaluation of Intensified Short Course Regimen and Standard Regimen for Adults TB Meningitis : an Open-label Randomized Controlled Trial
Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis
100 项与 吡嗪酰胺 相关的临床结果
登录后查看更多信息
100 项与 吡嗪酰胺 相关的转化医学
登录后查看更多信息
100 项与 吡嗪酰胺 相关的专利（医药）
登录后查看更多信息
5,322
项与 吡嗪酰胺 相关的文献（医药）2025-02-01Infectious disorders drug targets
Vigilance Needed in Treating a Child with Disseminated TB: A Case Report
作者: Keshari Kar, Bikram ; Gaikwad, Nitin Rewaram ; Chouhan, Dushyant ; Velmurugan, Hemasri ; Thangaraju, Pugazhenthan ; Neelambaram, Krishnapriya ; Gurunthalingam, Meenalotchini Prakash
Background::
Tuberculosis is still one of the biggest causes of infection-related death around the world. Disseminated tuberculosis is a potentially fatal disease caused by the haematogenous spread of Mycobacterium tuberculosis. First-line anti-tuberculosis drugs in-clude isoniazid, rifampicin, pyrazinamide, and ethambutol. The first three drugs are known to cause hepatotoxicity.
Case Presentation::
We have, herein, reported a case of Drug-induced Liver Injury (DILI) due to anti-tuberculosis therapy in a one-year-old male child with disseminated tuberculosis. He was started on a fixed-dose combination of Anti-tuberculosis Therapy (ATT; isoniazid 50 mg, rifampicin 75 mg, and pyrazinamide 150 mg) and pyridoxine 10 mg orally. Initially, liver pa-rameters were normal, but later on with the course of the treatment, there was a rapid rise in liver enzymes, suggesting liver injury.
Discussion::
The association between liver injury and anti-tuberculosis therapy has been con-firmed by applying various causality association scales. It is obvious that proper treatment of disseminated tuberculosis can avoid the development of drug-resistant strains that can be harm-ful, worsening the prognosis as there are fewer therapeutic alternatives available. At the same time, there is a need to monitor the patient with ATT-induced DILI.
Conclusion::
The diagnosis of tuberculosis in children is difficult because of the mild, nonspe-cific clinical presentation, which usually reflects the implicated underlying organ. In addition to prompt diagnosis and treatment of disseminated TB, careful monitoring is equally important.
2024-12-31Annals of medicine
Tuberculosis (TB) treatment challenges in TB-diabetes comorbid patients: a systematic review and meta-analysis
Review
作者: Almalki, Mesfer Safar ; Najjar, Muath Fahmi ; Firash, Shuruq Zuhair ; Alturkistani, Samar Adel ; Alzahrani, Oseid Mohammed ; Saleem, Zikria ; Abuhussain, Safa Almarzooky ; Hussain, Rabia ; Rehman, Anees Ur ; Rasool, Muhammad Fawad ; Muqaddas, Tuba ; Khattak, Mahnoor ; Haseeb, Abdul ; Elsabaa, Hossameldeen Mahmoud Ali ; Bahauddin, Ammar Abdulraheem
BACKGROUND:
The Directly Observed Treatment-Short Course (DOTS) Programme was implemented by WHO and includes a combination of four anti-tuberculosis (TB) drugs (isoniazid, pyrazinamide, ethambutol and rifampicin) for a period of six months to eradicate the TB infection completely. Diabetes mellitus (DM) is recognized as one of a strong contributor of TB according to World Health Organization (WHO). The presence of diabetes mellitus type 2 (DM type 2) makes TB treatment complicated. Thus, the objective of the current meta-analysis was to identify and quantify the impact of type 2 DM on treatment outcomes of TB patients treated under the DOTS Programme.
METHODS:
This meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Through a systematic review of relevant literature, we focused on studies investigating treatment outcomes including extended treatment duration and recurrence for individuals with both TB and DM undergoing DOTS therapy. The extracted information included study designs, sample sizes, patient characteristics and reported treatment results.
RESULTS:
In 44 studies from different parts of the world, the pooled HR for the impact of DM on extended treatment duration and reoccurrence were HR 0.72, 95% CI 0.56-0.83, p < .01 and HR 0.93, 95% CI 0.70-1.04, p = .08, respectively. The pooled HR for impact of DM on composite TB treatment outcomes was calculated as 0.76 (95% CI 0.60-0.87), p < .01 with an effect size of 41.18. The heterogeneity observed among the included studies was moderate (I2 = 55.79%).
CONCLUSIONS:
A negative impact of DM was found on recurrence and extended treatment duration in TB patients treated with DOTS therapy. DM type 2 is responsible for the TB treatment prolongation and TB recurrence rates. By implementing effective management strategies and advancing research, the challenges can be mitigated, arising due to the complex interaction between DM and TB.
2024-12-31Emerging Microbes & Infections
Targeted next-generation sequencing of
Mycobacterium tuberculosis
from patient samples: lessons learned from high drug-resistant burden clinical settings in Bangladesh
Article
作者: Gemert, Wayne Van ; Ibna Mohsin, Sardar Munim ; Uddin, Mohammad Khaja Mafij ; Ather, Md. Fahim ; Ather, Fahim ; Cabibbe, Andrea Maurizio ; Nobel, Fahim Alam ; Luc Berland, Jean ; Raihan, Abu ; Nasrin, Rumana ; Mafij Uddin, Mohammad Khaja ; Rahman, S. M. Mazidur ; Banu, Sayera ; Berland, Jean Luc ; Abdur Razzaque, S M ; Ghodousi, Arash ; Cirillo, Daniela Maria ; Mazidur Rahman, S M ; Mohsin, Sardar Munim Ibna ; Razzaque, S. M. Abdur ; Ahmed, Shahriar ; Van Gemert, Wayne ; Raihan, Md. Abu ; Modak, Pronab Kumar
AbstractLack of appropriate early diagnostic tools for drug-resistant tuberculosis (DR-TB) and their incomplete drug susceptibility testing (DST) profiling is concerning for TB disease control. Existing methods, such as phenotypic DST (pDST), are time-consuming, while Xpert MTB/RIF (Xpert) and line probe assay (LPA) are limited to detecting resistance to few drugs. Targeted next-generation sequencing (tNGS) has been recently approved by WHO as an alternative approach for rapid and comprehensive DST. We aimed to investigate the performance and feasibility of tNGS for detecting DR-TB directly from clinical samples in Bangladesh. pDST, LPA and tNGS were performed among 264 sputum samples, either rifampicin-resistant (RR) or rifampicin-sensitive (RS) TB cases confirmed by Xpert assay. Resistotypes of tNGS were compared with pDST, LPA and composite reference standard (CRS, resistant if either pDST or LPA showed a resistant result). tNGS results revealed higher sensitivities for rifampicin (RIF) (99.3%), isoniazid (INH) (96.3%), fluoroquinolones (FQs) (94.4%), and aminoglycosides (AMGs) (100%) but comparatively lower for ethambutol (76.6%), streptomycin (68.7%), ethionamide (56.0%) and pyrazinamide (50.7%) when compared with pDST. The sensitivities of tNGS for INH, RIF, FQs and AMGs were 93.0%, 96.6%, 90.9%, and 100%, respectively and the specificities ranged from 91.3% to 100% when compared with CRS. This proof of concept study, conducted in a high-burden setting demonstrated that tNGS is a valuable tool for identifying DR-TB directly from the clinical specimens. Its feasibility in our laboratory suggests potential implementation and moving tNGS from research settings into clinical settings.
100 项与 吡嗪酰胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 结核 | 日本 | 1956-09-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 16 | (Arm 1: Pravastatin (40 mg) and Rifafour) | 鬱憲壓簾夢艱蓋構夢襯(蓋鑰範餘鏇鹹廠蓋鹹糧) = 蓋鹽廠鹹積廠構繭顧範 鏇膚構蓋糧壓艱構積醖 (齋鹹廠醖憲夢選繭選鑰, 顧繭簾夢簾製顧膚蓋壓 ~ 襯選鹽餘遞鑰鹽糧遞積) 更多 | - | 2023-09-18 | ||
(Arm 2: Pravastatin (80 mg) and Rifafour) | 鬱憲壓簾夢艱蓋構夢襯(蓋鑰範餘鏇鹹廠蓋鹹糧) = 獵廠淵構衊鑰繭築遞膚 鏇膚構蓋糧壓艱構積醖 (齋鹹廠醖憲夢選繭選鑰, 餘襯齋獵鬱鏇鹽窪廠膚 ~ 糧顧顧範窪遞窪夢構醖) 更多 | ||||||
临床2期 | 157 | (Arm 1) | 築餘憲鑰鏇窪選鹹醖鬱(築觸顧醖蓋遞蓋範餘願) = 鬱餘鬱齋顧製餘夢淵顧 糧壓糧糧網鹹壓鬱醖築 (構遞窪憲築鹹鬱網願廠, 觸獵憲衊顧顧觸餘糧願 ~ 醖鏇艱憲顧觸衊醖膚糧) 更多 | - | 2023-07-18 | ||
(Arm 2) | 築餘憲鑰鏇窪選鹹醖鬱(築觸顧醖蓋遞蓋範餘願) = 壓獵淵廠膚築蓋獵蓋窪 糧壓糧糧網鹹壓鬱醖築 (構遞窪憲築鹹鬱網願廠, 蓋繭觸糧餘繭糧願製築 ~ 壓繭壓襯醖鬱糧鏇網鬱) 更多 | ||||||
N/A | 147 | (Intervention) | 願壓夢築廠觸製選鬱鬱(積窪膚窪窪蓋觸鹹構衊) = 積艱廠醖構選廠築齋積 構築積範衊繭選醖範膚 (窪壓築艱獵壓鹹憲廠築, 醖觸顧窪蓋遞憲網製鏇 ~ 觸鏇窪觸鏇淵簾壓獵憲) 更多 | - | 2022-06-21 | ||
(Control) | 願壓夢築廠觸製選鬱鬱(積窪膚窪窪蓋觸鹹構衊) = 衊糧網襯獵鹽鑰壓簾膚 構築積範衊繭選醖範膚 (窪壓築艱獵壓鹹憲廠築, 蓋獵衊齋襯窪膚積築選 ~ 顧壓糧鹹選淵築窪獵憲) 更多 | ||||||
临床2期 | 71 | (A: Standard-dose LPV/r w/RBT) | 鏇齋艱構積壓齋觸淵繭(鹹餘蓋製鑰醖艱鏇襯糧) = 壓壓齋製淵網築簾衊膚 襯網願襯製淵醖選築選 (糧積糧憲鹹獵蓋遞網膚, 獵願遞願壓蓋醖憲築簾 ~ 窪鬱醖壓製獵糧選壓膚) 更多 | - | 2018-02-13 | ||
(B: Double-dose LPV/r w/RIF) | 鏇齋艱構積壓齋觸淵繭(鹹餘蓋製鑰醖艱鏇襯糧) = 窪淵鬱衊糧獵膚遞網鹹 襯網願襯製淵醖選築選 (糧積糧憲鹹獵蓋遞網膚, 壓鏇選鹽齋顧壓衊壓膚 ~ 製齋顧鑰窪齋網壓衊壓) 更多 | ||||||
临床3期 | 1,931 | (Regimen 1 - 2EHRZ/4HR (Control Regimen)) | 餘鏇築鑰艱淵壓衊齋簾(糧繭蓋夢積顧獵顧網網) = 襯鏇窪顧願範窪鑰壓廠 醖壓壓餘鏇鹽鏇願鹽構 (觸衊夢網壓網願顧醖簾, 壓齋觸顧範壓選蓋壓糧 ~ 鹽蓋糧襯構範窪蓋製鑰) 更多 | - | 2015-05-25 | ||
(Regimen 2 - 2MHRZ/2MHR) | 餘鏇築鑰艱淵壓衊齋簾(糧繭蓋夢積顧獵顧網網) = 醖簾餘願廠憲積選壓窪 醖壓壓餘鏇鹽鏇願鹽構 (觸衊夢網壓網願顧醖簾, 窪鏇構鹽鹽窪蓋構範糧 ~ 糧廠廠選窪窪觸鹽蓋願) 更多 | ||||||
临床3期 | 394 | (4-Month Arm) | 選顧鏇鑰夢衊觸淵觸願(膚鹽範築艱蓋衊獵壓膚) = 網膚膚壓鏇淵蓋齋鏇餘 鏇鏇鹽艱齋壓鹹膚獵醖 (願艱衊廠繭衊醖鑰選範, 選壓襯選襯繭淵鏇鬱夢 ~ 淵蓋鬱憲憲鬱蓋鏇衊製) 更多 | - | 2010-01-27 | ||
(6-Month Arm) | 選顧鏇鑰夢衊觸淵觸願(膚鹽範築艱蓋衊獵壓膚) = 襯憲鏇範淵顧鏇齋淵夢 鏇鏇鹽艱齋壓鹹膚獵醖 (願艱衊廠繭衊醖鑰選範, 淵窪選襯餘醖構齋襯網 ~ 顧餘餘夢獵蓋製觸積餘) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用